Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor-Positive Breast Carcinoma”

652 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 652 results

Testing effectiveness (Phase 2)Study completedNCT04465097
What this trial is testing

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Who this might be right for
Breast Cancer
First Affiliated Hospital, Sun Yat-Sen University 30
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Not applicableUnknownNCT04683757
What this trial is testing

The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Ying Wang 288
Large-scale testing (Phase 3)Active Not RecruitingNCT05306340
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Who this might be right for
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Genentech, Inc. 373
Testing effectiveness (Phase 2)Ended earlyNCT01319539
What this trial is testing

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+11 more
National Cancer Institute (NCI) 12
Not applicableLooking for participantsNCT07242118
What this trial is testing

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

Who this might be right for
Breast Cancer Female
University of Kansas Medical Center 18
Very early researchLooking for participantsNCT05659797
What this trial is testing

FES BPET-DBT in Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
Abramson Cancer Center at Penn Medicine 20
Testing effectiveness (Phase 2)WithdrawnNCT01658176
What this trial is testing

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer
Large-scale testing (Phase 3)Not Yet RecruitingNCT07391774
What this trial is testing

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8+2 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT01522820
What this trial is testing

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Who this might be right for
Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma+62 more
Roswell Park Cancer Institute 18
Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing

PF-06873600 in People With Cancer

Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155
Testing effectiveness (Phase 2)Active Not RecruitingNCT02238808
What this trial is testing

See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers

Who this might be right for
Estrogen Receptor Positive Breast Cancer
AHS Cancer Control Alberta 19
Early research (Phase 1)Study completedNCT04132817
What this trial is testing

Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 12
Testing effectiveness (Phase 2)Study completedNCT02988986
What this trial is testing

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

Who this might be right for
Estrogen Receptor Positive Breast Cancer
The Methodist Hospital Research Institute 28
Not applicableStudy completedNCT06525675
What this trial is testing

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerLuminal Breast Cancer+2 more
MedSIR 419
Early research (Phase 1)Study completedNCT01840488
What this trial is testing

BN83495 Phase I in Post-menopausal Women

Who this might be right for
Breast Cancer
Ipsen 50
Testing effectiveness (Phase 2)Looking for participantsNCT06450873
What this trial is testing

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

Who this might be right for
Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
Mayo Clinic 100
Not applicableStudy completedNCT02773004
What this trial is testing

Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 203
Early research (Phase 1)Ended earlyNCT01281163
What this trial is testing

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Positive+4 more
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Load More Results
1,978